paclitaxel,cisplatin,gemcitabine
Not Tagged
[]
 1815 is out #gi23 1 no difference in mos between gap (14 mo) vs gem/cis (12.7 mo) 2 higher toxicity (&gt;grade 3/4) with gap (60%) vs gem/cis (45%) but no difference in discontinuation of therapy 3 potential benefit in la cc and gbc 
Hedinger Professor and Chair of Surgical Oncology at OHSU | Physician-in-Chief, Knight Cancer Institute | 🇧🇷 🇺🇸 ⚽️ in #PNW 🏔️ 🌲 🌊 🎣 Tweets/♥️ = own